UnitedHealth Group ($UNH)

1 Executive Summary

This memo documents a short-term, event-driven trade in UnitedHealth Group ($UNH) initiated in late August 2025. At the time, UNH was navigating an unprecedented crisis: the tragic murder of its UnitedHealthcare CEO, surging medical costs, and intensified regulatory scrutiny had driven the stock down over 50% from its 2024 highs. This confluence of negative catalysts created a climate of extreme fear, presenting what was assessed to be a significant market overreaction. The investment thesis was further validated by Berkshire Hathaway's newly disclosed $1.6 billion stake — a powerful institutional signal from one of the world's most respected value investors. The position was initiated at $302.29 on August 28, 2025, and successfully exited at $342.00 on September 17, 2025, capturing a +13.2% return in 20 days.

2 Situation Overview

The market sentiment surrounding UnitedHealth Group in mid-2025 was overwhelmingly negative. The company was reeling from the murder of UnitedHealthcare CEO Brian Thompson in December 2024, an event that had erased over $60 billion in market value and triggered an unprecedented public backlash against the managed care industry.^[1] This was compounded by industry-wide margin pressure from a surge in medical utilization rates (Medical Loss Ratio), a challenging regulatory environment for its core Medicare Advantage business, and a broader rotation out of defensive healthcare names. By August 2025, the stock had fallen to the low $300s from a 52-week high above $630 — a level not seen in over five years — as investors priced in a scenario of sustained earnings decline and permanent reputational damage.

3 Investment Thesis

The decision to initiate an event-driven position in UNH was predicated on three core tenets:

4 Valuation Analysis

At the entry price of $302, UNH was trading at valuation levels not seen in over five years. The compression in multiples was severe and, in our assessment, disproportionate to the fundamental deterioration in the business.

A discounted cash flow analysis using conservative assumptions — 8% long-term revenue growth (below the 10-year average of ~12%), a terminal growth rate of 2.5%, and a WACC of 9.0% — yielded an intrinsic value estimate of approximately $410–$440 per share, representing 35–45% upside from the entry price. This provided a substantial margin of safety.

5 Revenue & Business Structure

UnitedHealth Group operates through two primary segments: UnitedHealthcare (insurance) and Optum (health services). The dual-engine structure provides both scale and diversification, with Optum increasingly becoming the growth driver of the enterprise.

6 Trade Execution

The position was initiated on August 28, 2025, at an average price of $302.29. This entry was deliberately timed — rather than chasing the initial 14% spike on the day of the Berkshire disclosure (August 15), the trade was executed after the stock had consolidated and pulled back over the following two weeks, offering a more favorable entry with a clearly defined risk level. The position was closed on September 17, 2025, at an average price of $342.00, as the stock rallied into key technical resistance. The objective was to capture the value unlocked by the shift in market sentiment, not to establish a long-term core holding.

7 Conclusion

This trade in UnitedHealth Group serves as a case study in applying a contrarian, value-oriented framework to a short-term event-driven opportunity. By looking past the negative headlines and focusing on intrinsic value, institutional signals, and fundamental business strength, it was possible to identify and capitalize on a significant market dislocation — generating a +13.2% return in 20 days. The key lesson: when fear is at its peak and the business remains fundamentally sound, the risk/reward is often most favorable.